Kelley L Julian

11PUBLICATIONS
74CO-AUTHORS
Haematological tumoursApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Predictive and prognostic markersEvolution of developmental systemsGene and molecular therapy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (11)

|Jul 02, 2026
Real-World Outcomes with BCMA- and GPRC5D-Targeting Bispecific Antibodies in Plasma Cell Leukemia.

|Mar 28, 2026
Real-world outcomes with elranatamab in multiple myeloma: a multicenter analysis from the U.S. Multiple Myeloma Immunotherapy Consortium.

Andrew J Portuguese, James A Davis, Shahzad Raza

|Nov 28, 2025
The impact of extramedullary and paraskeletal plasmacytomas on treatment outcomes in multiple myeloma treated with teclistamab: U.S. Myeloma Immunotherapy Consortium real-world experience.

Aimaz Afrough, Danai Dima, Beatrice Razzo

|Oct 11, 2025
Predictors of Delayed Responses to Teclistamab in Multiple Myeloma After Initial Non-Response.

Rahul Banerjee, Gurbakhash Kaur, Beatrice M Razzo

|Sep 20, 2025
The past, present, and future of myeloma staging and risk prognostication.

Mehmet Baysal, Kelley Julian, Douglas Sborov

|Aug 08, 2025
Real-World Experience with Teclistamab for Relapsed/Refractory Multiple Myeloma from the US Myeloma Immunotherapy Consortium.

Beatrice M Razzo, Shonali Midha, Andrew J Portuguese

Pageof 2

Frequent Collaborators

10 joint publications

James A Davis

9 joint publications

Megan M Herr

9 joint publications

Jack Khouri

9 joint publications

Surbhi Sidana